On Monday, June 7, 2021, Biogen received FDA approval for Aduhelm (Aducanumab). Aduhelm is the first disease modifying, FDA approved therapy indicated for certain patients with Alzheimer’s Disease (AD).
Specialty Infusion Centers is providing Aduhelm infusion therapy and will work diligently to ensure that you receive treatment safely and in line with your referring provider’s guidance.
Administration and Dosage:
After initial pre-treatment, the recommended dosage of ADUHELM™ is 10 mg/kg. It’s administered as an intravenous (IV) infusion over approximately one hour every four weeks and at least 21 days apart.
Common Side Effects:
The more common side effects of ADUHELM™ include headaches, confusion, dizziness, vision changes, and nausea.
Please CLICK HERE to review FAQs for ADUHELM™
Ready to Get Started?
In order to get started, your specialist must first determine that you are a candidate for this treatment and then contact us to begin the referral process.
ADUHELM™ is indicated to treat:
- Alzheimer’s disease